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Abstract
Alzheimer’s disease remains a significant health burden that affects millions in the
United States. This research pursued to shed light on the modifiable risk factors and help
individuals at high risk for Alzheimer’s disease minimize the chances of cognitive decline. A
search of literature was conducted on databases such as PubMed, Google Scholar, and Medline.
Randomized control trials, longitudinal studies, systematic reviews, and meta-analyses were
identified and included in the paper. The modifiable risk factors that play a role in the onset and
progression of Alzheimer’s disease include stress, inadequate physical exercise, lack of sleep
hygiene, and lack of social engagement. However, in the studies that focused on modifying these
factors, results showed an improved cognitive performance. Other modifiable factors such as
alcohol and dietary intake, including omega-3 fatty acids and carotenoid-rich foods, were found
to slow cognitive decline. Additionally, the MIND, DASH, and the Mediterranean diet are
recommended for high-risk patients. The general implication of these findings is that modifying
these risk factors for high-risk patients can lead to better cognitive performance and slow AD
progress. Future studies can focus on conducting longitudinal factors such as alcohol intake due
to the inconsistent findings documented in this research. The burden of Alzheimer’s disease can
be reduced nationwide by effectively addressing these modifiable risk factors.
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Introduction
Alzheimer's disease (AD) presents a significant healthcare burden for the United States.
Over 6.2 million Americans age 65 and older currently live with AD. The number of people with
AD is estimated to increase to 12.7 million people by 2050.1 It is the most common cause of
dementia and affects more women than men. While the cause of AD remains unknown, multiple
non-modifiable and modifiable factors are associated with its development. The most noteworthy
risk factors include old age, family history, and carrying the APOE-e4 gene.1 There are
additional risk factors that are modifiable but can increase the risk of AD development. Amongst
these factors include lifestyle modifications such as changes in stress management, dietary
intake, sleep, and exercise that can reduce one's risk for AD. In addition, it has been found that
persons with a past medical history of cardiovascular disease risk factors such as HTN, diabetes
mellitus, and traumatic brain injuries are more prone to AD. However, other modifiable risk
factors such as more formal years of education and remaining socially and cognitively engaged
may reduce the risk of AD.1 Since cognitive impairment increases with the progression of AD, it
is important to identify the relationship between modifiable risk factors and AD. According to
Wang et al,2 these interventions effectively manage AD, but current evidence to support this
assertion is still low. Therefore, healthcare providers can utilize these interventions to improve
outcomes for AD patients.
Since there is no cure for AD, current treatment focuses on memory retention, cognitive
and physical functioning, and slowing the condition's progression. The increasing prevalence of
AD among older people underlines the need for increased awareness about modifiable risk
factors. Therefore, understanding these risk factors can better facilitate the management of this
disease. Ultimately, this research intends to help individuals at high risk for AD prevent and
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minimize their chances of cognitive decline by shedding light on the following modifiable risk
factors discussed in this work. The research question for this paper is, "In Alzheimer's disease,
how does modifying risk factors impact clinical progression?" The article is outlined as follows.
First, a background on the modifiable risk factors and then literature surrounding their impact of
AD progression. This paper will conclude with a discussion of recommendations and future
research directions based on the current literature.
Background
Pathophysiology
Alzheimer's disease (AD) is a progressive neurodegenerative disease that commonly
leads to dementia. Since the exact causes of AD are not fully understood, there are proposed
theories of the pathogenesis of AD. One of the most influential theories known is the amyloid
cascade hypothesis and the Tau hypothesis. The amyloid hypothesis proposes that the abnormal
accumulation of the amyloid-beta (Aβ) protein leads to the extracellular formation of neuritic
plaques. In contrast, the tau hypothesis suggests an intracellular accumulation of the tau protein
due to the hyperphosphorylation from the Aβ aggregation leading to the formation of
neurofibrillary tangles. Though it is unknown, it is frequently believed that the Aβ aggregation is
the initial pathological event in AD and triggers the subsequent cascade of events such as the
neurofibrillary tangles, an abnormal accumulation of tau. This causes tau to detach from
microtubules and form threads that eventually tangle inside neurons. Additionally, these changes
lead to blockage of the neuron's transport system, harming synaptic communication.3 Thus,
understanding the AD disease process can help implement better interventions for modifiable
risk factors.
Clinical Features
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Given that AD has a very slow progression, its clinical manifestations present much later
than the initial pathological changes in the brain. This results in a long preclinical stage that often
lasts up to 20-30 years before signs and symptoms of cognitive impairment appear. In the typical
presentation of AD, the age of onset is 65 and older. Following the preclinical stage, some of the
earlier manifestations of AD are impairment in executive function, judgment, and most
significant, memory. For a clinical diagnosis of AD, the cardinal symptom of memory
impairment must be present. Memory deficits are frequently the most common initial symptom
of AD. The type of memory impairment typically follows a distinctive pattern such that the
episodic memory is impacted first, and then procedural memory is affected later in the disease.
As the disease progresses, Alzheimer's patients are faced with behavioral and psychological
symptoms such as social disengagement, irritability, and apathy.
Diagnostics
AD is typically high in suspicion when a patient of older age presents with a progressive
memory decline. However, before working up AD in particular, it is important to rule out other
changeable causes of dementia. A patient presenting with initial AD symptoms would first
undergo various neuropsychological tests followed by lab testing to dismiss adjustable causes of
dementia such as vitamin B12 deficiency or hypothyroidism. Healthcare professionals can use
various approaches to confirm AD diagnosis. Family members are asked about changes in
behavior and personality and then conduct memory, attention, language, and problem-solving
tests. Additionally, the doctor will conduct blood and urine tests to identify other possible causes
of the problem. Lastly, computed tomography, magnetic resonance imaging, along with positron
emission tomography are executed to exclude other possible causes of AD symptoms. 4 Overall,
these tests help doctors determine the presence of AD and its current progression.
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Management
Active management of AD involves pharmacological and non-pharmacological
interventions. The medications sanctioned by the FDA for AD treatment are rivastigmine,
galantamine, donepezil, memantine, and memantine combined with donepezil. However, these
medications are not curative; rather, they are used to slow down the neuronal damage caused by
AD.1 Apart from these interventions, non-pharmacologic therapies are initiated for AD to ensure
improvement in cognitive function and quality of life (QoL). Interventions such as computerized
memory training, listening to music, physical exercise, and special lighting are often utilized.
According to Wang et al,2 music therapy improves cognitive function and mental well-being.
Additionally, regular physical activity decreases cognitive declines and reduces the risk of AD .2
Therefore, once a patient is diagnosed with AD, these interventions are utilized to slow its
progression and reduce cognitive decline.
Lifestyle Modification
Stress Management
The relationship between stress and AD is documented in various studies. Firstly,
Hoeijmakers et al5 examine whether stress in early life increases vulnerability for AD. The
authors summarize information from preclinical literature with a specific focus on biological
substrates that mediate the relationship between these two conditions. Early-life stress elevated
glucocorticoid levels and corticotropin release factor signaling. Additionally, stress increases
amyloid and tau pathology and reduces synaptic connectivity and hippocampal neurogenesis,
which leads to cognitive decline due to less cognitive reserve. These findings indicate that stress
experienced particularly in one's childhood may hinder healthy aging and modify AD
development. Other studies corroborate these findings. Caruso et al6 indicate that elevated
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glucocorticoid levels from high-stress levels can trigger cellular, molecular, and behavioral
imbalances that resemble the pathological features of AD. In particular, stress enhances the
amyloid ß precursor protein and tau phosphorylation that were previously noted as major
contributory factors to the development of AD by causing synaptic dysfunction and neuronal
death.6 Thus, stress increases vulnerability to AD.
In another study, Quanes and Popp7 reviewed the literature to document how high
cortisol levels enhance the threat of dementia and AD. This study indicates that enhanced
cortisol levels are connected with poor mental functioning, lower episodic memory, executive
functioning, and social cognition. The authors conclude that elevated cortisol levels have
detrimental effects on cognition and lead to AD.7 In another study, Justice8 examines the
relationship between stress and AD. The findings from this article indicate that stress exacerbates
AD pathogenesis. Moreover, AD can also lead to stress as it disrupts neural circuits that mediate
stress responses.8 The link between these two conditions is demonstrated in these studies. Stress
management through different strategies is included in the discussion section. Therefore, stress
management is essential to prevent cognitive decline and possible AD development.
Dietary Intake
Omega-3
Omega-3 fatty acids have demonstrated effectiveness in enhancing memory functions in
patients diagnosed with AD. Marti and Fortique9 conducted a systematic review of fourteen
RCTs to determine the effectiveness of this intervention in cognitive function. The results from
this review show that omega-3 fatty acids can improve individual domains of cognitive function
such as working memory, executive function, perceptual speed, and verbal memory. The
systematic review concludes that of the fourteen studies, ten of them showed a positive outcome
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in that omega-3 supplementation might improve cognitive function.9 Of the remaining studies
showed no positive outcome, it was found that the participants in those studies had an average
younger age than the ones that had a positive outcome. Another study by Nolan et al10 attempted
to demonstrate the potential benefits of combining omega-3 fatty acids with Xanthophyll
carotenoids. The study included three experiments that focused on patients with mild and
moderate AD and those free from the condition. The first group was given Xanthophyll
carotenoids only supplementation, the second group was given Xanthophyll carotenoids and fish
oil, while the third group of participants without AD received Xanthophyll carotenoids. Similar
to Marti and Fortique9, the findings show that participants in the second group had positive
cognition outcomes from the additional supplementation of omega-3. However, the authors
conclude that more scientific evidence is needed to confirm this significant observation.10 The
findings from this study indicate that omega-3 fatty acids consumption can decrease cognitive
decline associated with AD.
While omega-3 fatty acids are effective; some studies indicate that it does not entirely
improve cognitive function. In a systematic review of seven studies, Canada et al11 found that
omega-3 fatty acids are beneficial during disease onset. The effectiveness of these supplements
at this stage is due to slight impairment in cognitive function. However, there is no sufficient
evidence to support omega-3 supplementation in severe AD cases. 9 In another systematic
review and meta-analysis, Araya-Quintanilla et al12 examine whether there is sufficient scientific
evidence to support omega-3 supplementation in patients with AD. The study includes six
randomized controlled trials (RCTs). Contrary to study,9 the results from this paper show that
there is still a lack of consistent evidence that supports omega-3 supplementation.12 Omega-3
supplementations can be used during the early stages of AD to prevent the decline in cognitive
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function. While this intervention can slow cognitive decline, this evidence indicates that it is only
effective in earlier stages of AD.
Carotenoid-rich Foods
Carotenoids rich-food are effective for reducing cognitive decline connected to AD. In
the study by Nolan et al,10 the researchers found that combining carotenoids with omega-3
enhanced cognitive outcomes for AD patients. These findings are upheld in a recent metaanalysis of RCTs by Davonelli et al,13 examining the relationship between carotenoids and
cognitive outcomes. The analysis included 9 studies with a total of 4402 participants ranging
between 45 to 78 years. Though the results from this study indicate that carotenoids enhanced
cognitive outcomes for the participants, the findings were geared more towards healthy subjects
than those with dementia or AD.13 Additionally, Lakey-Beitia14 examines how the chemistry and
structure of carotenoid compounds act against Aβ aggregation. The findings indicate that
carotenoids possess dominant anti-amyloidogenic molecules that can prevent AD by inhibiting
Aβ aggression. Similar to Nolan's study, these findings support the view that carotenoids
effectively avert cognitive decline in patients with AD.
Furthermore, Beydoun et al15 evaluate longitudinal data from 1251 participants to
determine the effects of carotenoids, vitamins A, C, and Eon favorable cognitive outcomes. The
results show that an interaction between vitamins A, C, and carotenoids was not consistent and
rather found that carotenoids and vitamin E are linked to positive outcomes in the memory
performance.15 Another study by Tan and Norhaizan 16 tried to establish the effectiveness of
carotenoids in preventing age-related diseases. The findings show that carotenoids reduce
oxidative stress and promote healthy aging by slowing the progress of age-related diseases.16
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Ultimately, through these various studies, it is evident that the role of carotenoids is pivotal in the
prevention of AD by enhancing an individual's cognitive outcomes.
Mediterranean and DASH Diet
Some of the most common modifiable risk factors, such as type II diabetes, hypertension,
and obesity, can be reduced by changes in one's dietary patterns. Miranda et al17 examine how
the Mediterranean diet consisting of fruits, vegetables, olive oil, and moderate wine intake can
prevent AD. Through these foods, one gets vitamins, polyphenols, and unsaturated fatty acids
that reduce oxidative stress. Another important role of this diet highlighted by Miranda et al17 is
that it possesses an anti-inflammatory effect inhibiting the pathogenesis of AD. As a result, the
Mediterranean diet improves AD risk factors by slowing the progression of this condition. 17
Another study by Van de Brink18 established that the Mediterranean and the Dietary approaches
to Stop Hypertension (DASH) were associated with less cognitive decline and could lower the
risk of developing AD. Moreover, the review found that adherence to the Mediterranean-DASH
Intervention for Neurodegenerative Delay (MIND) was linked to better cognitive performance. 17
The evidence from these studies supports the view that both the Mediterranean and DASH diets
can slow cognitive decline and decrease the possibility of AD. Patients should be encouraged to
adhere to these diets to modify risk factors and promote better cognitive outcomes.
Cherian et al19 also examine how the MIND diet can slow cognitive decline after stroke. The
study included 106 participants with a clinical history of stroke. The MIND diet components
comprised whole grains, leafy greens, vegetables, beans, nuts, lean meats, and poultry. The
participants were also expected to reduce consumption of cheese, butter, fried foods, and sweets.
The results show that participants had a slower global cognitive decline rate. The authors
conclude that adherence to the MIND diet is linked to slow cognitive decline through these
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results. In another study, Berendsen et al20 examined how long-term adherence to the MIND diet
was related to cognitive function and decline among American women. The study included
16,058 women aged 70 and over. The findings from this study show that adherence to the MIND
diet was linked to better verbal memory but not cognitive decline. The authors recommend the
need for more studies to confirm the effectiveness of the MIND diet on slowing cognitive
decline.20 Overall, the diet is an effective intervention for slowing AD progression.
Alcohol
The relationship between alcohol consumption and AD has been researched in several
studies. In particular, an observational study conducted by Andrews et al21 shows that light-tomoderate alcohol consumption decreases the risk of AD. However, this study utilized twosample Mendelian randomization (MR) approach to analyze how alcohol consumption
dependence and alcohol use disorder were linked to late-onset AD. The findings from the study
demonstrated that alcohol consumption was linked to earlier onset of AD while alcohol
dependence was linked to delayed age of onset survival. This delayed onset was associated with
survivor bias in the study. 21 Some of the findings from this study are corroborated by
Venkataraman et al22 in a literature review propose that alcohol adds to the cognitive burden of
dementia. Indeed, alcohol misuse and dependence cause cognitive impairment. 22 These results
confirm that the level of alcohol intake determines the rate of cognitive decline and can
contribute to AD.
At the same time, Topiwala et al23 examined the relationship between moderate alcohol
consumption and cognitive decline. The researchers adopted a longitudinal study that comprised
550 men and women who were not alcohol dependent. Through a 30-year follow-up, the results
showed that high alcohol consumption was linked to adverse brain outcomes. Light drinking did
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not offer the participants any protective effects. The study concluded that alcohol consumption
even at moderate levels can lead to adverse brain outcomes. For instance, persons consuming
over 30 units weekly had the highest risk of cognitive decline, while those consuming 14-21
units showed right-sided hippocampal atrophy. Moreover, light drinkers (1-7 units per week) did
not have any protective effects against cognitive decline compared to abstainers.23 However,
results from a study by Zhang et al24 indicate that low to moderate alcohol consumption is linked
to better global cognition scores. However, these findings appear stronger among white
participants than blacks. The racial differences in this study limit the generalization of the
findings to other populations. The question of alcohol consumption and AD need more research
with the inclusion of more participants. For example, diverse participants such as Blacks,
Hispanics, Native Americans, and Asian Americans can be included in future studies to help
predict the link between alcohol consumption and AD. Therefore, the relationship between
alcohol and AD needs further examination.
Sleep Hygiene
Emerging evidence has linked the lack of sleep hygiene to the risk of AD. Burke et al25
study examined whether sleep medication could offer protection against AD and whether APOE
e4 carriers that showed signs of sleep disturbance were at an increased risk of AD. A secondary
analysis of data from the National Alzheimer's Coordinating Center was conducted. The results
showed that sleep disturbance is linked to eventual AD development. However, sleep medication
was found to mediate this relationship. Additionally, APOE e4 carriers had a significant risk of
AD. Similarly, Sabia et al26 examined how sleep duration was related to the risk of dementia; it
was found that lower sleep duration was linked to increased dementia risk. Notably, the 25-year
follow-up study indicated that people with a normal sleep duration of more than seven hours had
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a lower risk of dementia.26 These findings underline the positive link between sleep and AD.
People should be encouraged to observe better sleep hygiene to lower their risk of dementia.
At the same time, other studies 27,28 have affirmed the positive link between lack of sleep
and AD. Westwood27 conducted a self-reported study comprising 2457 men and women to
determine the relationship between sleep duration and early neurodegeneration. The findings
indicate that prolonged sleep is a possible marker of neurodegeneration. These results can be
used to identify people at higher risk of progressing to clinical dementia. In another study,
Brzecka28 link sleep disorders to AD, describing how sleep disturbance causes circadian
fluctuations in amyloid- β concentration in the interstitial brain fluid.28 The accumulating
evidence suggests that sleep disturbance can lead to cognitive decline and AD development.
Sabia et al26 note that having at least seven hours of sleep each day can reduce the risk of AD.
Therefore, individuals at risk of AD should be advised to observe appropriate sleep hygiene to
minimize progressive cognitive decline.
Physical Activity and Exercise
Physical activity and exercise are protective against various chronic diseases. Several
studies have been conducted to determine how physical exercise is beneficial in slowing AD
progress. The efficacy of physical exercise has been examined in RCTs 29,30 in patients with AD.
Fonte et al29 conducted a study to determine how physical exercise was effective for AD and
mild cognitive impairment (MCI). The results suggest that constant physical exercise is linked to
the mitigation of cognitive decline. However, it is only effective when constantly applied and not
periodically.29 In another RCT, Cox et al30 examined how physical exercise is beneficial for
older patients at risk of AD. The study involved participants above 60 years with MCI or
subjective memory complaints. Physical activity was associated with benefits such as leg
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strength and better fat mass distribution. These benefits reduced cardiovascular risk, which in
return minimized cognitive decline. Exercises such as walking, cycling, and swimming are often
designed by considering health problems and other limitations.30 Additionally, moderateintensity aerobic physical activity is also recommended for AD patients.32 Physical exercise is a
useful intervention to slow cognitive decline in patients with AD.
Various meta-analyses and systematic reviews have also underlined the efficacy of
physical exercise for older persons with AD. Cunningham et al31 performed a systematic review
and meta-analysis to establish the effect of physical exercise on older adults. The study included
24 studies that focused on older adults above 60 years. Results indicated that physical exercise
for these older adults reduced cardiovascular and cancer risk. Additionally, the risk of AD,
dementia and depression was also reduced through physical exercise. The articles included in
this study showed that the QoL and cognitive function of the participants improved significantly
as a result of physical activity. Similarly, Jia et al32 conducted a meta-analysis that supports these
findings. The meta-analysis included 13 RCTs comprising 673 participants diagnosed with AD.
Physical activity interventions in each of these studies resulted in significant cognitive
improvements. Moreover, the frequency of interventions did not result in a significant difference
in the cognitive improvements.32 These reviews and meta-analyses support the notion that
physical activity slows cognitive decline for patients with AD and those at-risk.
Medical Comorbidities
Hypertension
The link between hypertension (HTN) and AD has been discussed in various studies.
Lennon et al33 conducted a systematic review and meta-analysis to establish the link between
midlife HTN and AD. While the authors found 3426 publications addressing the issue, only
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seven were eligible based on their meticulous design. The findings showed a significant
association between HTN and AD. Midlife systolic HTN increased the risk of AD by 18-25%,
while diastolic HTN was not linked to AD. Another systematic review and meta-analysis by
Hughes et al34 established how antihypertensive therapy lowered the risk of dementia and HTN.
The authors included 12 trials comprising 92,135 participants in this study. The results indicated
that lowering blood pressure through antihypertensive therapy led to a lower risk of dementia
and cognitive impairment.34 The results from these two studies support the assertion that HTN
increases the risk of AD. Controlling HTN through pharmacological and non-pharmacological
interventions is necessary to slow the cognitive decline associated with AD. Patients diagnosed
with HTN should be advised to adhere to treatment to reduce the risk of AD in old age.
Additionally, adherence to HTN management among AD patients should be encouraged to
improve outcomes.
Diabetes Mellitus
The link between diabetes mellitus (DM) and the risk of AD is still a debate. However,
several studies have sought to determine the link between the two medical conditions. Hersi et
al35 conducted a systematic review to determine the risk factors linked to the onset and
progression of AD. The review included 65 studies published between 2010 and 2012. The
evidence from these articles indicates that DM increases the risk of AD onset and progression. In
another study conducted by Hayden,36 type 2 diabetes mellitus (T2DM) increased the risk of
late-onset AD. T2DM increases exposure of the brain's neurovascular unit through ultrastructural
remodeling. This tips the balance of the brain and increases the risk of late-onset AD.36 An
emphasis on insulin adherence can help patients with DM manage symptoms effectively while
reducing the risk of AD onset and progression.
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Head Trauma
Several studies have linked head trauma to the increased risk of AD. Zhang et al37
conducted a meta-analysis of cohort studies to determine the relationship between traumatic
brain injury (TBI) and the risk of AD. The researchers analyzed 17 studies that focused on the
relationship between head trauma and AD. The results from this study indicate that the risk of
AD was enhanced among individuals with traumatic brain injury. Indeed, moderate and severe
traumatic brain injury was linked to an increased risk of AD. Similarly, LoBue et al38 support
these findings by underlining the connection between brain injury and earlier age of onset of AD.
The findings showed that individuals with TBI and Apoe4 carriers had the earliest mean age of
AD. TBI was associated with increased cognitive decline regardless of Apoe4 and gender. 37
Lastly, Tolppanen et al39 conducted a case-control study to determine the association between
head injuries and AD. The study was conducted among 70,719 community dwellers diagnosed
with clinical AD in Finland. The findings showed a strong association between head or brain
injury in the AD disease process.39 Head trauma can increase AD progression. Interventions to
slow the progress of these conditions should focus on individuals with a history of head trauma.
Psychosocial Factors
Social Engagement
Social engagement (SE) is linked to significant health benefits such as reduced rates of
mortality and reduced risk of depression. The link between social engagement and AD has been
discussed in various studies. Zhou et al40 determine how SE and its change are linked to
dementia risk. The longitudinal study was conducted in a 9-year follow-up and involved 7511
older Chinese adults over 65 years. The results indicated that enhanced SE was linked with lower
risk dementia. Moreover, participants with lower levels of SE were at a higher risk of dementia.
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Notably, during the 9-year follow-up, 338 persons among the participants developed dementia.40
These findings are corroborated by Biddle et al,41 who examines the relationship between SE and
Amyloid-β-related cognitive decline. The study was also longitudinal and included 217
community-dwelling cognitively normal adults. The findings showed that the level of SE
determined the risk of cognitive change among high-risk individuals. So lower SE was seen as a
marker of neurocognitive vulnerability in older adults. Spending time with family, friends, and
community groups increases social engagement and help older adults remain active. 41 Older
adults should be encouraged to remain socially active to slow the cognitive decline associated
with AD.
Apart from longitudinal studies, systematic reviews and meta-analyses have found
positive links between SE and AD. In a systematic review of sixty-five studies, Hersi et al35
established an association between SE and AD. Notably, evidence suggested that lower SE was
associated with an increased risk of AD. The results from the review indicate that lower SE, poor
social networks, and loneliness increase the risk of AD. For example, widowhood, being single,
or living alone enhanced the risk of AD.35 These findings on loneliness are supported by
Sundstrom et al,42 who examined whether loneliness increased the risk of dementia and AD. The
study included 1,905 participants with a follow-up time of 20 years. During the study period, 428
developed dementia, 221 developed AD, 157 had vascular dementia, while 50 had other types of
dementia. These results indicate that loneliness is a significant risk factor for AD. The authors
note that any subjective reports of loneliness among the elderly should not be ignored.43 Thus,
the level of social engagement can enhance or reduce the rate of AD progression.
While these studies underline the link between loneliness and AD, a systematic review
and meta-analysis by Penninkilampi et al43 arrived at different findings. The study attempts to
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determine the connection between SE, loneliness, and the risk of dementia. Poor SE was found to
increase the risk of dementia, while good SE was protective. SE engagement indices such as
poor social support the poor social network increased the risk of dementia. However, the
relationship between loneliness and dementia was insignificant. The authors encourage
implementing interventions that target social isolation and lack of SE to prevent dementia. 43
Healthcare professionals caring for older adults should encourage them to remain socially active
as this is protective against AD.
Cognitive Reserve
Cognitive reserve (CR) refers to the brain's capacity to retain cognition despite
underlying cerebral damage. Van Loenhoud et al44 tries to determine the relationship between
CR and clinical progress across the AD spectrum. The study included 839 participants who were
Aβ positive. 175 participants had normal cognition, 437 had MCI, and 227 had AD dementia.
These participants were followed for 24 months. The results indicate that among Aβ-positive
participants, a higher CR decreased clinical progress of AD. However, higher amounts of Aβ
inevitably increased the rate of cognitive decline among individuals with dementia. 44 In another
study, Soldan et al45 establish whether the level of CR and AD biomarkers modified the change
in cognition. Notably, higher CR was linked to enhanced cognitive performance. Nevertheless,
these higher rates did not modify the rate of cognition change. Moreover, higher CR was linked
to quicker cognitive decline after symptom commencement of MCI.45 The results show that CR
mediates the connection between pathology and cognitive function. CR can delay symptom onset
but will not reduce the rate of cognitive decline.
Depression and Anxiety
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Depression and anxiety are established risk factors in AD. Eijansantos et al46 examine the
relationship between a history of psychiatric disease and AD. The study involved 1500 AD
patients with depression, anxiety, PTSD, bipolar, and schizophrenia. The results indicated that
patients with depression and anxiety had a slightly younger-onset than others. The authors
conclude that the diagnosis of depression and anxiety possess additive impacts on AD
pathology. Thus, Similarly, Santabarbara et al47 performed a meta-analysis of cohort studies to
determine the link between anxiety and all-cause dementia. The analysis included eight studies
comprising 29,608 participants. The results indicate that anxiety was linked to an increased risk
of all-cause dementia. The authors note that treatment of anxiety can reduce the incidence of
dementia.48 Another study by Canton-Habas48 focuses on depression as a risk factor for
dementia and AD. The case-control study involved 125 controls. The findings showed that
depression increased the risk of AD which underlines the need for effective interventions to
address these conditions early.
Additionally, Almeida et al49 investigated whether antidepressant use among patients
with depression reduces the risk of dementia. The study involved 4922 cognitively healthy men
and women and was conducted for 14-years. The results indicated that antidepressant use did not
decrease the risk of dementia. The relationship between dementia and depression was only
evident during the first five years of follow-up. Additionally, older men with a history of
dementia had a higher susceptibility for dementia. The authors concluded that depression is a
marker of dementia and not necessarily a modifiable factor.47 Other treatment alternatives should
be considered for individuals diagnosed with depression and anxiety.
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Methods
A systematic search of the literature was conducted on various databases. These
databases include Google Scholar, PubMed, and Medline. Search terms utilized include
modifiable risk factors of Alzheimer's disease. Other terms are stress and AD, diet intake and
AD, and psychosocial risk factors for AD. Additionally, search results were limited to the last
five years. The articles retrieved include those published in English and those translated from
other languages such as Spanish. Moreover, the articles retrieved included meta-analyses,
systematic reviews, randomized control trials, reviews, and longitudinal studies. Studies
published beyond the last five years and expert opinions were excluded from the literature
review.
Discussion
The expected increase in the prevalence of AD in the U.S.1 underlines the need to
example how modifiable factors affect its clinical progression. The main purpose of the literature
review is to analyze how modifiable risk factors impact AD's progress. This review found that
some modifiable risk factors can accelerate AD progression while others have the potential to
slow the progression of AD. The review focused on stress, diet, alcohol, sleep hygiene,
physical activity, and social engagement. Thus, this section discusses these factors and what
healthcare professionals can do to slow AD progression.
Impact of Stress Management and the Progression of AD
The findings from the literature review show that stress plays a critical role in AD
progression. Stress is positively linked to the onset of AD.5,6,7,8 In their summary of pre-clinical
literature, Hoeijmakers et al5 established that stress plays a role in disturbing glucocorticoid
levels and corticotrophin release. Indeed, the summary by these authors indicates that stress
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intensifies cognitive decline as people who experienced stress in early life have a less cognitive
reserve (CR). Other studies 44, 45 have found that CR mediates AD pathology and cognitive
function. Yet another study by Caruso et al6 found that stress results in cellular, molecular, and
behavioral imbalances that reflect AD features. Notably, stress can lead to synaptic dysfunction
and neuronal death that is linked to AD. The results from this study highlight the critical role that
stress plays in AD progress. Individuals who experience early-life stress are likely to experience
an earlier onset of AD.
Each of these studies shows that stress plays a significant role in AD progression. Any
reports of stressors should not be ignored by healthcare providers but documented adequately to
initiate interventions. These interventions can ensure that onset of AD is delayed, or its progress
slowed. The interventions to address stress include physical exercise and mediation. These
interventions should be encouraged for patients that report any symptoms of stress. The
conclusion from the review of these studies is that stress management is an effective strategy to
slow and delay AD progression. The lack of effective stress management leads to exacerbation
of AD symptoms.
Impact of Dietary Intake of the Progression of AD
The review indicated that maintaining a healthy diet is linked to slowing AD progression.
Various studies 9, 10, 11, 12 established that omega-3 fatty acids enhance cognitive functions.
Omega-3 fatty acids can provide benefits such as improved working memory, executive
function, and verbal memory. The omega-3 fatty acids can be provided to those at risk of AD or
those diagnosed with the condition to slow cognitive decline. Combining these foods with
carotenoids has also shown significant efficacy in patients with AD. For example, Nolan et al 10
found that Xanthophyll carotenoids combined with omega-3 fatty acids resulted in improved
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cognitive outcomes for patients with mild and moderate AD.10 However, the findings from this
study are only experimental. Conducting more studies such as systematic reviews and metaanalyses can provide stronger evidence linking this dietary intake to improved cognitive
outcomes. Generally, these foods effectively slow the cognitive decline in AD patients by
improving memory functions.
While omega-3 fatty acids are considered effective, other studies 11, 12 present differing
evidence. Canada et al11 established that omega-3 fatty acids are only impactful during AD onset
due to slight cognitive impairment. These findings are substantiated by Araya-Quintanilla et al,12
who notes that evidence on omega-3 fatty acids supplementation is still inconsistent. However,
due to some studies underlining the efficacy of omega-3 fatty acids, this diet should continue to
be recommended for patients at risk of AD or those with clinically diagnosed AD. More studies
supporting the effectiveness of omega-3 fatty acids are needed to enhance dietary care for AD
patients.
Apart from omega-3 fatty acids, patients with AD are often advised to take carotenoidrich foods or supplements. Carotenoid-rich foods include yams, kale, spinach, watermelon, bell
peppers, and tomatoes. Some studies 13,14 have shown that carotenoid-rich foods can slow the
progression of AD. Davonelli et al13 found that carotenoid-rich foods improved cognitive
outcomes among patients with AD. The majority of the participants in the study included in the
meta-analysis13 reported improved memory functions due to taking a carotenoid-rich diet.
Additionally, another study by Lakey-Beitia14 confirms that the chemical structure of carotenoid
compounds can prevent AD. However, this finding needs to be confirmed in more studies to
provide clinical evidence that supports carotenoid effectiveness.
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Another study by Beydoun et al15 recommended combining carotenoids with vitamin E to
improve memory performance. This study's findings indicate that participants who received this
vitamin E and carotenoids had improved cognitive outcomes. However, the interaction between
vitamins A and C and carotenoids still needs more inquiry. Yet another study by Tan and
Norhaizan16 found that taking carotenoid-rich foods as preventive against age-related diseases.
The findings indicate that carotenoids are effective in decreasing oxidative stress and promoting
healthy aging. The major implication from the results in these studies is that carotenoids should
always be a consideration for patients diagnosed with AD or those at an enhanced risk of
developing the condition.
Diet is also an effective intervention for the management of AD risk factors such as
T2DM and HTN. Miranda et al17 demonstrate that patients who take the Mediterranean diet
experienced slow AD progress in one study. Other diets such as DASH and MIND are also
recommended for patients with AD. Van de Brink18 provides evidence that links these diets to
improved cognitive performance. Additionally, Cherian et al. 19 established that the MIND diet
slows cognitive decline after stroke. The dietary guidelines include increasing the consumption
of whole greens, beans, lean meats, and poultry while reducing the consumption of fried foods,
cheese, and sweets. While these dietary guidelines are beneficial, their effectiveness is
significantly reliant on patient adherence. Notably, Berendsen et al20 found that long-term
adherence to the MIND diet among American women improved cognitive performance.
Nevertheless, the findings show that while MIND improves cognitive performance, it was not
linked to slower cognitive decline. Thus, these diets can be recommended to impact risk factors
and slow AD progression.
Impact of Alcohol on the Progression of AD
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Alcohol is a major risk factor for chronic diseases such as hypertension. The link between
alcohol and AD progression has been examined in various studies, as shown in the literature
review. Several studies 21, 22 have linked alcohol consumption to AD. Andrews et al21 found that
alcohol consumption results in the early onset of AD. This assertion is supported by Venkaraman
et al,22 which established that alcohol use, misuse, and dependence contribute to cognitive
impairment. Similar conclusions are shared by Topiwala et al,23 who conducted a 30-year
follow-up and found that excessive alcohol consumption was linked to adverse cognitive
outcomes. One of the most significant findings from this study is that even light drinking
contributed to poor cognitive outcomes. However, findings in other studies 24,35 have shown that
light-to-moderate consumption decreases the risk of AD onset. The findings from these studies
21,22,23,24,35

are conflicting on the impact of alcohol intake on AD progression. Nevertheless, due

to the contributing aspect of alcohol to chronic diseases such as hypertension, it is essential to
moderate consumption. More clinical studies are necessary to provide substantial evidence on
the link between alcohol intake and AD.
Impact of Sleep Hygiene of the Progression of AD
Proper sleep hygiene ensures that the body maintains sufficient rest. Lack of sleep
hygiene has been linked to AD. Burke et al25 established that sleep disturbance was linked to the
early onset of AD. These findings are corroborated by Sabia et al,26 who notes that maintaining a
sleep duration of at least seven hours had protective effects against AD. Additionally, for people
at risk of developing AD, prolonged sleep has been underlined as a marker for cognitive
decline.27 Lastly, Brzecka28 found a link between sleep disturbance and AD. The findings from
each of these studies indicate that lack of adequate sleep hygiene is a significant risk factor that
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can contribute to AD progression. Interventions for patients diagnosed with sleep disorders are
necessary to prevent cognitive decline and delay AD onset.
Impact of Physical Exercise of the Progression of AD
Physical exercise is linked to significant health benefits. In AD, physical exercise has
been shown to slow cognitive decline. Fonte et al29 suggest that constant physical exercise can
mitigate cognitive decline in AD patients. Another study by Cox et al30 established that physical
exercise for older adults diagnosed with AD reduced cardiovascular risk and decreased cognitive
decline. Also, Cunningham et al31 established that cardiovascular and dementia risk was
significantly reduced through adequate physical exercise. Another study by Jie et al32 established
that physical exercise led to cognitive improvements in patients diagnosed with AD. The major
implication of these findings is that physical exercise is recommendable for patients diagnosed
with AD. These exercises can be individualized depending on the patient's diagnosis.
Impact of Social Engagement on the Progression of AD
Another modifiable protective risk factor is social engagement SE. Enhanced levels of
social interactions have been found to reduce the risk of AD. Zhou et al40 established that older
adults with high SE had a lower risk of developing dementia. Moreover, Biddle et al41 showed
that cognitive change in some older adults was linked to the level of SE. Hersi35 found a direct
link between lower levels of SE to increased risk of AD. Older adults who had a poor social
network experience loneliness leading to a significant cognitive decline.43 Other contributing
factors include loss of partners and being single. Maintaining active social networks can ensure
that the progression of AD is slowed. Healthcare providers should encourage patients to maintain
active interactions with friends and family to reduce AD progression.
Management of High-Risk Patients for AD
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The literature review has shown that various strategies can manage patients at high risk of AD.
The first effective stress management strategy is to implement stress management interventions
for patients at risk of AD. Through effective management of stress, the progression of AD will
be slower as the patient will maintain better cognitive function. Additionally, persons who
experience early-life stress should be prioritized for these interventions as they are at high risk
for AD.15 The stress management techniques can be combined with other interventions to ensure
effectiveness in AD prevention.
Apart from stress, interventions for patients at high risk should focus on dietary intake.
Consuming omega-3 fatty acids, vitamin E, and a carotenoid-rich diet should be recommended
for patients due to their protective effects against cognitive decline.10,13,14,15 The diet can be
developed by working collaboratively with dieticians to ensure that patient meals are
individualized. Moreover, aspects such as cultural background should be considered to ensure
that the foods recommended are culturally appropriate. Additionally, diets such as DASH,
MIND, and Mediterranean are effective in preventing cognitive decline.18 Patients at high risk
for AD should be put on these diets to delay the onset of AD and slow its progression. Each of
these diets can improve cognitive performance and lower the AD burden.
While this literature review found conflicting evidence about the role of alcohol in AD,
at-risk patients should be advised to moderate consumption. Indeed, patients consuming the
Mediterranean diet are advised to take wine moderately.17 Excessive alcohol consumption should
be avoided as it is detrimental to the brain and can contribute to other risk factors such as
hypertension and diabetes. Additionally, patients at high risk should be advised to maintain
effective sleep hygiene of at least seven hours to prevent cognitive decline.25 27 Closely
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monitoring patients at high risk of AD is also recommended as prolonged sleep patterns may be a
feature of cognitive decline.27
Lastly, patients at high risk for AD can be managed through adequate physical exercise
and social engagement. Physical exercise helps these patients address cardiovascular risk, which
is linked to AD progression. For example, Jie et al. 32 indicate that physical exercise improves
cognitive health for patients diagnosed with AD. Additionally, maintaining active social
networks is necessary for patients at high risk of AD. Patients such as widows or those who live
alone should be encouraged to maintain active social lives as this provides some prevention
against the onset of AD. These patients can be connected to social groups within their
communities to ensure social engagement. Thus, physical exercise and social engagement are
important risk factors that can ensure AD onset is delayed and its progression slowed.
Conclusion
Alzheimer's disease remains a significant health burden in the U.S. Various factors
impact AD progression. This paper has documented how different modifiable risk factors impact
AD progression. While other factors can slow or prevent AD, others accelerate the clinical
progression of AD. The research conducted so far indicates that modifiable risk factors such as
stress management, dietary intake, sleep hygiene, and physical activity are linked to Alzheimer's
disease. Other factors such as medical and psychosocial history play a role in AD onset and
progress. However, the research conducted through this literature review indicates that some of
these factors can be modified to impact AD progression. Factors such as stress can be managed
through effective intervention. Additionally, dietary intakes that comprise omega-3 fatty acids
and carotenoid-rich foods should be recommended. The MIND, DASH, and Mediterranean diets
are also effective in patients with AD or those at risk of developing the condition due to their
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impact on cognitive performance. Overall, the progression of AD can be slowed by modifying
these risk factors.
Research also indicates that moderate alcohol consumption offers protection, while
excessive consumption can lead to cognitive decline. Moreover, the research has established that
maintaining sleep hygiene and engaging in physical exercise effectively prevent AD. Patient
education about these factors is necessary to improve knowledge about AD and enhance
preventive measures. Additionally, research has linked medical history factors such as
hypertension, diabetes, and head trauma to AD. Patients diagnosed with these health conditions
should be prioritized for interventions that slow cognitive decline. Lastly, other factors such as
lack of social engagement, cognitive reserve, depression, and anxiety contribute to the onset and
progress of AD. Healthcare professionals should consider these factors when caring for AD
patients.
While research about the significance of modifiable risk factors is extensive, future
studies can focus on several issues. More longitudinal studies can examine the role that alcohol
intake plays in cognitive decline. Additionally, future studies can perform systematic reviews
and meta-analyses of these studies to provide more evidence on risk factors such as dietary
patterns across cultures and how they affect AD. Lastly, future studies should include patients
with an early onset of AD as this will help identify common modifiable risk factors.
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